Allogene reports Q4 2022 net loss $94.8M, cash $576.5M; pipeline advances

Allogene Therapeutics, Inc.

2022-FY EPS reported -$2.32 revenue$243,000

Net loss Q4 2022 $94.8M ($0.66/share); full year net loss $332.6M ($2.32/share).
Cash, cash equivalents and investments $576.5M as of Dec 31, 2022; expects 2023 cash burn ~$250M, runway into 2025.
Initiated ALPHA2 Phase 2 trial of ALLO-501A in R/R LBCL; enrollment expected to complete 1H 2024.
Phase 1 data: ALLO-501A single dose FCA90 showed 67% ORR, 58% CR rate, median DoR 23.1 months.
UNIVERSAL trial of ALLO-715 in R/R MM: 67% ORR, 42% VGPR+ rate, median DoR 9.2 months.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Allogene Therapeutics, Inc. reported financial results for fourth quarter and year ended December 31, 2022.

Period: fourth quarter and year ended December 31, 2022
Result: reported results

Exact text from the filing

On February 28, 2023, Allogene Therapeutics, Inc. (the “Company”) provided a corporate update and announced its financial results for the fourth quarter and year ended December 31, 2022 in the press release attached hereto as Exhibit 99.1 and incorporated herein by reference.

View on SEC.gov

20 earnings releases filed in the last 30 days. Browse all earnings releases →

Allogene Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001737287-23-000017

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.